GB0126879D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB0126879D0
GB0126879D0 GBGB0126879.6A GB0126879A GB0126879D0 GB 0126879 D0 GB0126879 D0 GB 0126879D0 GB 0126879 A GB0126879 A GB 0126879A GB 0126879 D0 GB0126879 D0 GB 0126879D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0126879.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0126879.6A priority Critical patent/GB0126879D0/en
Publication of GB0126879D0 publication Critical patent/GB0126879D0/en
Priority to BR0213906-5A priority patent/BR0213906A/pt
Priority to HK05100883.5A priority patent/HK1068546B/en
Priority to PT02772624T priority patent/PT1446124E/pt
Priority to JP2003541842A priority patent/JP4694127B2/ja
Priority to DK02772624T priority patent/DK1446124T3/da
Priority to CA2464758A priority patent/CA2464758C/en
Priority to CNB028267958A priority patent/CN1298328C/zh
Priority to IL16174402A priority patent/IL161744A0/xx
Priority to NZ532525A priority patent/NZ532525A/en
Priority to DE60213845T priority patent/DE60213845T2/de
Priority to AU2002337382A priority patent/AU2002337382B2/en
Priority to KR1020047007020A priority patent/KR100959607B1/ko
Priority to EP02772624A priority patent/EP1446124B1/en
Priority to US10/494,704 priority patent/US20050043395A1/en
Priority to ES02772624T priority patent/ES2269769T3/es
Priority to AT02772624T priority patent/ATE335488T1/de
Priority to MXPA04004355A priority patent/MXPA04004355A/es
Priority to SI200230408T priority patent/SI1446124T1/sl
Priority to PCT/GB2002/005021 priority patent/WO2003039551A1/en
Priority to ARP020104292A priority patent/AR037346A1/es
Priority to IL161744A priority patent/IL161744A/en
Priority to ZA200403455A priority patent/ZA200403455B/en
Priority to NO20042365A priority patent/NO328048B1/no
Priority to CY20061101619T priority patent/CY1106259T1/el
Priority to US13/290,730 priority patent/US20120252827A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0126879.6A 2001-11-08 2001-11-08 Combination therapy Ceased GB0126879D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
KR1020047007020A KR100959607B1 (ko) 2001-11-08 2002-11-06 Ｚｄ6474 및 탁산을 포함하는 조합 요법
US10/494,704 US20050043395A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
PT02772624T PT1446124E (pt) 2001-11-08 2002-11-06 Terapia de combinação compreendendo zd6474 e um taxano
JP2003541842A JP4694127B2 (ja) 2001-11-08 2002-11-06 Ｚｄ６４７４とタキサンとを含む組み合わせ療法
DK02772624T DK1446124T3 (da) 2001-11-08 2002-11-06 Kombinationsterapi, der omfatter ZD6474 og et taxan
CA2464758A CA2464758C (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
CNB028267958A CN1298328C (zh) 2001-11-08 2002-11-06 包括应用zd6474和紫杉烷的联合疗法
IL16174402A IL161744A0 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
NZ532525A NZ532525A (en) 2001-11-08 2002-11-06 Combination therapy comprising ZD6474 and a taxane used in cancer treatment
DE60213845T DE60213845T2 (de) 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan
AU2002337382A AU2002337382B2 (en) 2001-11-08 2002-11-06 Combination therapy comprising ZD6474 and a taxane
BR0213906-5A BR0213906A (pt) 2001-11-08 2002-11-06 Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
EP02772624A EP1446124B1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
HK05100883.5A HK1068546B (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane
ES02772624T ES2269769T3 (es) 2001-11-08 2002-11-06 Terapia de combinacion ee comprende zd6474 y un taxano.
AT02772624T ATE335488T1 (de) 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan
MXPA04004355A MXPA04004355A (es) 2001-11-08 2002-11-06 Tratamiento de combinacion que comprende zd6474 y un taxano.
SI200230408T SI1446124T1 (sl) 2001-11-08 2002-11-06 Kombinacijska terapija, ki obsega ZD6474 in taksan
ARP020104292A AR037346A1 (es) 2001-11-08 2002-11-08 Terapia de combinacion
IL161744A IL161744A (en) 2001-11-08 2004-05-03 Use of zd6474 and taxane in the manufacture of a medicament for the treatment of cancer and pharmaceutical compositions and kits comprising such compounds
ZA200403455A ZA200403455B (en) 2001-11-08 2004-05-06 Combination theraphy comprising ZD6474 and a taxane.
NO20042365A NO328048B1 (no) 2001-11-08 2004-06-07 Farmasoytisk preparat omfattende ZD6474 og et taxan, sett omfattende samme samt anvendelse av samme for fremstilling av medikament for behandling av sykdom
CY20061101619T CY1106259T1 (el) 2001-11-08 2006-11-09 Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
US13/290,730 US20120252827A1 (en) 2001-11-08 2011-11-07 Combination of therapy comprising zd6474 and a taxane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy

Publications (1)

Publication Number Publication Date
GB0126879D0 true GB0126879D0 (en) 2002-01-02

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0126879.6A Ceased GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy

Country Status (22)

Country Link
US (2) US20050043395A1 (https=)
EP (1) EP1446124B1 (https=)
JP (1) JP4694127B2 (https=)
KR (1) KR100959607B1 (https=)
CN (1) CN1298328C (https=)
AR (1) AR037346A1 (https=)
AT (1) ATE335488T1 (https=)
AU (1) AU2002337382B2 (https=)
BR (1) BR0213906A (https=)
CA (1) CA2464758C (https=)
CY (1) CY1106259T1 (https=)
DE (1) DE60213845T2 (https=)
DK (1) DK1446124T3 (https=)
ES (1) ES2269769T3 (https=)
GB (1) GB0126879D0 (https=)
IL (2) IL161744A0 (https=)
MX (1) MXPA04004355A (https=)
NO (1) NO328048B1 (https=)
NZ (1) NZ532525A (https=)
PT (1) PT1446124E (https=)
WO (1) WO2003039551A1 (https=)
ZA (1) ZA200403455B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
JP7737455B2 (ja) * 2020-12-22 2025-09-10 ハンミ ファーマシューティカル カンパニー リミテッド Ｓｏｓ１阻害剤としての新規キナゾリン誘導体化合物及びその用途｛ｎｏｖｅｌ ｑｕｉｎａｚｏｌｉｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｓ ｓｏｓ１ ｉｎｈｉｂｉｔｏｒｓ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
PT910382E (pt) * 1996-04-26 2003-10-31 Genaera Corp Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (en) * 2003-07-10 2010-08-25 AstraZeneca AB Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
IL161744A0 (en) 2005-11-20
EP1446124B1 (en) 2006-08-09
NO20042365L (no) 2004-06-07
CN1298328C (zh) 2007-02-07
DE60213845D1 (de) 2006-09-21
WO2003039551A1 (en) 2003-05-15
JP2005511597A (ja) 2005-04-28
US20050043395A1 (en) 2005-02-24
MXPA04004355A (es) 2004-08-11
DE60213845T2 (de) 2007-03-29
CA2464758C (en) 2010-09-28
JP4694127B2 (ja) 2011-06-08
ATE335488T1 (de) 2006-09-15
CA2464758A1 (en) 2003-05-15
ZA200403455B (en) 2005-08-29
ES2269769T3 (es) 2007-04-01
NO328048B1 (no) 2009-11-16
PT1446124E (pt) 2006-12-29
HK1068546A1 (en) 2005-04-29
IL161744A (en) 2012-01-31
CN1612738A (zh) 2005-05-04
NZ532525A (en) 2006-11-30
KR100959607B1 (ko) 2010-05-27
CY1106259T1 (el) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DK1446124T3 (da) 2006-11-13
KR20050043779A (ko) 2005-05-11
EP1446124A1 (en) 2004-08-18
AR037346A1 (es) 2004-11-03
US20120252827A1 (en) 2012-10-04
BR0213906A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
EP1463438A4 (en) ENDOMURAL THERAPY
GB0119152D0 (en) Therapeutic agents
GB0126879D0 (en) Combination therapy
GB0113841D0 (en) Therapeutic agents
GB0118383D0 (en) Therapeutic methods
GB0120347D0 (en) Therapeutic agents
GB0108930D0 (en) Therapeutic agents
GB0113839D0 (en) Therapeutic agents
GB0114867D0 (en) Therapeutic agents
GB0117060D0 (en) Therapeutic agents
GB0113842D0 (en) Therapeutic agents
GB0111191D0 (en) Therapeutic agents
GB0108485D0 (en) Combination therapy
GB0101933D0 (en) Therapy
GB0113843D0 (en) Therapeutic agents
IL147696A0 (en) Combination therapy
GB0108982D0 (en) Therapeutic agents
GB0120345D0 (en) Therapeutic agents
GB0119803D0 (en) Therapeutic agents
GB0128122D0 (en) Therapeutic use
GB0119828D0 (en) Therapeutic agents
GB0124029D0 (en) Combination therapy
GB0108821D0 (en) Therapy
GB0108817D0 (en) Therapy
GB0108816D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)